-transparent.png){kind=logo}
Nicotinic acid concentrations in the serum over 80 mug/100 ml induce at the start of high dosage nicotinic acid therapy an acute rise in bilirubin to 1-3mg/100 ml serum. Even after postprandial administration there are clearly raised bilirubin concentrations in the serum. After treatment for 1 week with 0.5 g nicotinic acid daily by mouth the bilirubin increase is no longer detectable. The increased bilirubin concentrations in the serum are apparently the result of a transient inhibition of glucuronyl-transferase and is not a symptom of an acute liver disorder. When starting high dosage nicotinic acid therapy, therefore, disorders of the bilirubin metabolism and liver function must be excluded by differential diagnosis in doubtful cases. Further investigations are necessary to see whether the high concentrations of nicotinic acid in the serum cause competition with other drugs for the bilirubin-specific glucuronyl-transferase.
K Dietmann, and
H Stork
January 1981,
Therapie,
K Dietmann, and
H Stork
April 1980,
Anasthesie, Intensivtherapie, Notfallmedizin,
K Dietmann, and
H Stork
October 1973,
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Dietmann, and
H Stork
January 1977,
Ceskoslovenska gastroenterologie a vyziva,
K Dietmann, and
H Stork
October 1977,
Archiv fur Gynakologie,
K Dietmann, and
H Stork
January 1981,
La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris,
K Dietmann, and
H Stork
March 1954,
Medizinische Klinik,
K Dietmann, and
H Stork
January 1981,
Arzneimittel-Forschung,
K Dietmann, and
H Stork
February 1976,
Deutsche medizinische Wochenschrift (1946),
K Dietmann, and
H Stork
February 1981,
Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca,
